Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation de... von Michalarea, Vasiliki, Lorente, David, Lopez, Juanita, Carreira, Suzanne, Hassam, Hasina, Parmar, Mona, Sathiyayogan, Nitharsan, Turner, Alison, Hall, Emma, Serrano Fandos, Sonia, Seeramreddi, Satyanarayana, Decordova, Shaun, Swales, Karen, Ruddle, Ruth, Raynaud, Florence, Tunariu, Nina, Attard, Gerhardt, Molife, L. Rhoda, Banerji, Udai, Plummer, Ruth, de Bono, Johann S., Yap, Timothy A.

Volltext

A pharmacokinetic (PK) and pharmacodynamic (PD) biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 (RO) in patien... von de Miguel Luken, Maria Jose, Roda, Desamparados, Perez Lopez, Raquel, Jimenez, Begona, Hassam, Hasina, Sathiyayogan, Nitharsan, Parmar, Mona, Turner, Alison Joanne, Hall, Emma, Tunariu, Nina, Molife, L Rhoda, Yap, Timothy Anthony, De Bono, Johann Sebastian, Banerji, Udai

Volltext

Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tum... von Harris, Samuel John, de Miguel Luken, Maria Jose, Roda Perez, Desamparados, Perez Lopez, Raquel, Parmar, Mona, Prathapan, Vasanthi, Hassam, Hasina, Turner, Alison Joanne, Serrano Fandos, Sonia, Hall, Emma, Tovey, Holly, Tunariu, Nina, Lopez, Juanita Suzanne, Yap, Timothy Anthony, De Bono, Johann S., Banerji, Udai

Volltext

Long-term survivors in phase I clinical trials: Who are they and what predicts their survival? von Jimenez Rodriguez, Begona, Michie, Caroline Ogilvie, Lorente, David, Hassam, Hasina, Toloui, Helen Nicole, Lovosgaldeano, Jimena, Goswami, Debarati, De Bono, Johann Sebastian, Kaye, Stan B, Banerji, Udai, Molife, L Rhoda

Volltext